Harnessing anticalin technology as a multi-targeted treament approach for vision loss

利用 anticalin 技术作为视力丧失的多靶点治疗方法

• 批准号: nhmrc : 1122132
• 负责人: A/Pr Lyndell Lim
• 金额: $ 42.78万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/harnessing-anticalin-technology-vision-loss/946876
• 关键词: Harnessing; anticalin; technology; multi; targeted

Diabetes is a leading cause of vision loss and blindness worldwide and is caused by two factors called VEGF and Ang2, which damage blood vessels. Current treatments only block VEGF and many patients do not respond and suffer irreversible damage to sight. We have used ground-breaking anticalin technology to make a new drug (PRS-AUS1) that blocks both VEGF and Ang2. Studies will be performed in animal models and move to patients where we expect improved outcomes compared to current treatments.

糖尿病是世界范围内视力丧失和失明的主要原因，是由两种叫做VEGF和Ang2的因素引起的，这两种因素会损害血管。目前的治疗方法只能阻断VEGF，许多患者没有反应，并遭受不可逆的视力损害。我们已经使用突破性的抗alin技术制造了一种新药（PRS-AUS1），它可以阻断VEGF和Ang2。研究将在动物模型中进行，并转移到患者身上，我们希望与目前的治疗方法相比，结果会有所改善。